✦ LIBER ✦

Pleuroperitoneal shunts as treatment for refractory chylothorax following surgery for congenital beast disease

✍ Scribed by Karen S. Rheuban; Irving L. Kron; Martha A. Carpenter; Howard P. Gutgesell; Bradley M. Rodgers

Book ID: 119168876
Publisher: Elsevier Science
Year: 1991
Tongue: English
Weight: 233 KB
Volume: 17
Category: Article
ISSN: 1558-3597
DOI: 10.1016/0735-1097(91)91505-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pleuroperitoneal shunts for refractory c

Pleuroperitoneal shunts for refractory chylothorax after operation for congenital heart disease

✍ Rheuban, Karen S.; Kron, Irving L.; Carpenter, Martha A.; Gutgesell, Howard P.; 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 242 KB

Negative pressure ventilation as haemody

Negative pressure ventilation as haemodynamic rescue following surgery for congenital heart disease

✍ L. S. Shekerdemian; I. Schulze-Neick; A. N. Redington; A. Bush; D. J. Penny 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 58 KB

Mortality as an outcome measure followin

Mortality as an outcome measure following cardiac surgery for congenital heart disease in the current era

✍ Ravi R. Thiagarajan; Peter C. Laussen 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB

rFVIIa in the treatment of persistent he

rFVIIa in the treatment of persistent hemorrhage in pediatric patients on ECMO following surgery for congenital heart disease

✍ ALEX VELDMAN; CHRISTOPH NEUHAEUSER; HAKAN AKINTUERK; JOSEF THUL; JOHANNES GEHRON 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

Recombinant human soluble tumor necrosis

Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation

✍ Alessandro Busca; Franco Locatelli; Filippo Marmont; Cristina Ceretto; Michele F 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB 👁 2 views

## Abstract Etanercept is a recombinant human soluble tumor necrosis factor (TNF‐α) receptor fusion protein that inhibits TNF‐α, a major mediator in the pathogenesis of graft‐versus‐host disease (GVHD). The purpose of our study was to evaluate the safety and efficacy of etanercept therapy in 21 pat